Top Markets
Coin of the day
Gongwin Biopharm Holdings Co., Ltd. Gongwin Biopharm Holdings Co., Ltd.

Gongwin Biopharm Holdings Co., Ltd.

6617
Clasificación en acciones #13682
Gongwin Biopharm Holdings Co., Ltd. is a clinical-stage biopharmaceutical... Gongwin Biopharm Holdings Co., Ltd. is a clinical-stage biopharmaceutical company specializing in the development of oncology therapeutics. The company's robust pipeline features several drug candidates, including PTS302, which has successfully concluded Phase III clinical trials for lung cancer. Additionally, PTS100 is currently progressing through Phase II clinical trials for liver cancer, while PTS-02 is being developed to address adenoid cystic carcinoma, and PTS500 targets malignant pleural effusion. Established in 2014, Gongwin Biopharm is headquartered in Taipei, Taiwan.
Precio por acción
$3.88
Capitalización bursátil
$470.23M
Cambio (1 día)
1.24%
Cambio (1 año)
19.67%
País
TW
Comercio Gongwin Biopharm Holdings Co., Ltd. (6617)

Categoría

Ganancias de Gongwin Biopharm Holdings Co., Ltd. (6617)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Gongwin Biopharm Holdings Co., Ltd., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Gongwin Biopharm Holdings Co., Ltd. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$6.46B -
US
- -
US
$2.17B -
US
- -
US
$708.86M -
AU